Impax Laboratories Beats on Both Top and Bottom Lines

Seth Jayson, The Motley Fool
Updated

Impax Laboratories (NAS: IPXL) reported earnings on May 1. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Impax Laboratories beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share dropped significantly. GAAP earnings per share increased significantly.


Gross margins dropped, operating margins dropped, net margins grew.

Revenue details
 Impax Laboratories tallied revenue of $148.5 million. The 13 analysts polled by S&P Capital IQ predicted a top line of $127.7 million on the same basis. GAAP reported sales were 15% higher than the prior-year quarter's $128.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.37. The 13 earnings estimates compiled by S&P Capital IQ averaged $0.20 per share. Non-GAAP EPS of $0.37 for Q1 were 29% lower than the prior-year quarter's $0.52 per share. GAAP EPS of $1.55 for Q1 were much higher than the prior-year quarter's $0.18 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 39.0%, 970 basis points worse than the prior-year quarter. Operating margin was 5.8%, much worse than the prior-year quarter. Net margin was 71.0%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $117.2 million. On the bottom line, the average EPS estimate is $0.06.

Next year's average estimate for revenue is $477.0 million. The average EPS estimate is $0.34.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 159 members out of 172 rating the stock outperform, and 13 members rating it underperform. Among 46 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Impax Laboratories a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is hold, with an average price target of $18.70.

The article Impax Laboratories Beats on Both Top and Bottom Lines originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement